In an adult patient at risk for multidrug‑resistant Enterobacter infection, would ceftolozane/tazobactam (Zerbaxa), colistin, or ceftazidime/avibactam (Avycaz) be reasonable empiric therapy options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Empiric Treatment of Multidrug-Resistant Enterobacter Infections

Ceftazidime-avibactam (Avycaz) is the most reasonable empiric option among the three agents you listed for MDRO Enterobacter, while ceftolozane-tazobactam (Zerbaxa) should NOT be used and colistin should be reserved only as a last resort when newer agents are unavailable or the organism is resistant to all other options.

Rationale for Ceftazidime-Avibactam (Avycaz)

Ceftazidime-avibactam is specifically recommended by multiple guidelines for carbapenem-resistant Enterobacterales (CRE), which includes multidrug-resistant Enterobacter species 1, 2. The 2022 ESCMID guidelines conditionally recommend ceftazidime-avibactam for severe CRE infections if active in vitro, with moderate to low quality evidence 1. The FDA label confirms activity against Enterobacter cloacae across multiple infection types including cIAI, cUTI, and HABP/VABP 3.

Key advantages:

  • Broad coverage: Active against KPC and OXA-48-like carbapenemase producers, which are common resistance mechanisms in Enterobacter 4
  • Proven efficacy: 30.6% of MDR Enterobacterales showed susceptibility to ceftazidime-avibactam, with carbapenem-resistant K. pneumoniae showing 33.5% susceptibility 5
  • Monotherapy acceptable: Guidelines explicitly state combination therapy is NOT recommended when using ceftazidime-avibactam for susceptible CRE 1

Dosing: 2.5 g IV every 8 hours infused over 2 hours 3

Why NOT Ceftolozane-Tazobactam (Zerbaxa)

Ceftolozane-tazobactam has NO reliable activity against Enterobacter species and should be avoided. This agent is specifically designed for difficult-to-treat resistant Pseudomonas aeruginosa 1, 2. The guidelines make clear distinctions:

  • Recommended for CRPA (carbapenem-resistant P. aeruginosa) 1
  • NOT mentioned in any guideline recommendations for Enterobacterales or CRE 1, 2

Using ceftolozane-tazobactam for Enterobacter would be off-target therapy with high likelihood of treatment failure.

Why Colistin is Last-Line Only

Colistin should be avoided whenever possible due to significant toxicity and inferior outcomes 4. However, it remains an option when:

  • The organism is resistant to all newer beta-lactam/beta-lactamase inhibitors
  • Ceftazidime-avibactam and other preferred agents are unavailable
  • Susceptibility testing confirms activity

When colistin must be used for CRE:

  • Always use combination therapy with at least one other active agent (e.g., tigecycline, meropenem if MIC ≤8 mg/L, or aminoglycosides) 1, 2
  • Colistin showed 96% susceptibility against carbapenem-resistant organisms, the highest among tested agents 5
  • Toxicity concern: 7 of 31 patients (22.6%) developed acute kidney injury requiring CRRT when colistin was combined with ceftazidime-avibactam 6

Dosing for colistin: 5 mg colistin base activity (CBA)/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV every 12 hours 2

Critical Caveats

  1. Metallo-β-lactamase producers: If the Enterobacter produces a metallo-β-lactamase (MBL), ceftazidime-avibactam will NOT work. In this scenario:

    • Use aztreonam + ceftazidime-avibactam combination 1
    • Consider cefiderocol if available and susceptible 1, 4

  2. Renal dosing is essential: Failure to adjust for renal impairment significantly increases mortality risk. In one trial, patients with CrCl 30-50 mL/min who received inadequate dosing had 19.5% mortality versus 7.0% with proper dosing 3

  3. Always obtain susceptibility testing: Empiric therapy should be narrowed based on culture results and resistance mechanism identification 2

  4. Infectious disease consultation strongly recommended for all MDRO infections 2

Empiric Algorithm Summary

First-line empiric: Ceftazidime-avibactam 2.5 g IV q8h (infused over 2 hours)

If MBL suspected/confirmed: Aztreonam + ceftazidime-avibactam combination OR cefiderocol

If all newer agents unavailable or resistant: Colistin-based combination therapy (colistin + tigecycline or colistin + carbapenem if MIC ≤8 mg/L)

Never use: Ceftolozane-tazobactam for Enterobacter

References

Related Questions

What are the differences between multidrug‑resistant (MDR), pan‑resistant, and carbapenem‑resistant Enterobacterales (CRE) organisms?
What antibiotic regimen should be used for an adult with an infected amputation and a carbapenem‑resistant Enterobacteriaceae (CRE) infection who is allergic to meropenem?
For a severe carbapenem‑resistant Gram‑negative infection, especially metallo‑β‑lactamase‑producing, should I use colistin or aztreonam plus ceftazidime‑avibactam (Zerbaxa) as the preferred therapy?
For a wound abscess caused by Enterobacter that was previously resistant to cephalosporins and is currently being treated with vancomycin and meropenem, what is the appropriate antibiotic regimen and should vancomycin be continued?
What is the recommended treatment for a urinary tract infection caused by Acinetobacter baumannii, coagulase‑negative Staphylococcus, and Enterobacter cloacae?
Can epoetin alfa (Procrit) and iron sucrose (Venofer) be administered on the same day?
Which bronchodilator should be used for a patient classified as GOLD group A (low exacerbation risk and few symptoms)?
What is the recommended management for leprosy, including drug regimens for paucibacillary and multibacillary disease, monitoring, and treatment of reactions?
What is the most appropriate ADHD screening tool for a 13‑year‑old?
How should a severe sunburn affecting the shoulder and neck be managed?
In an elderly nursing home resident with dementia and anxiety who has been taking fluoxetine 20 mg daily and lorazepam (Ativan) 0.5 mg twice daily for several years and now presents with worsening confusion and somatic preoccupations, what is the best treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.